Incannex cancels all Series A Warrants, eliminating 347.2M shares of potential dilution

Incannex Healthcare Inc.

Cancelled remaining 172M Series A Warrants for $12.2M via ATM facility; combined with earlier tranche removes 347.2M shares.
CEO Joel Latham says cancellation eliminates significant dilution ahead of Phase 2 RePOSA topline data for IHL-42X in July 2025.
IHL-42X is a potential first-in-class oral therapy for obstructive sleep apnea, a condition with no FDA-approved drug.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.